SB623
Total Payments
$13.3M
Transactions
1,857
Doctors
5
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $2.3M | 366 | 1 |
| 2018 | $4.1M | 953 | 1 |
| 2017 | $6.9M | 538 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.3M | 1,854 | 100.0% |
| Consulting Fee | $5,500 | 2 | 0.0% |
| Travel and Lodging | $298.20 | 1 | 0.0% |
Payments by Type
Research
$13.3M
1,854 transactions
General
$5,798
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke (ACTIsSIMA) | Sunovion Pharmaceuticals Inc. | $9.2M | 2 |
| Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke | Sunovion Pharmaceuticals Inc. | $4.1M | 0 |
Top Doctors Receiving Payments for SB623
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Toledo, OH | $13.2M | 1,840 |
| , M.D | Psychiatry | Austin, TX | $63,708 | 6 |
| , M.D | Physical Medicine & Rehabilitation | Overland Park, KS | $45,614 | 8 |
| , MD | Neuromuscular Medicine | Irvine, CA | $4,500 | 1 |
| , M.D., PH.D | Neurological Surgery | Atlanta, GA | $1,000 | 1 |
| , MD | Specialist | Pittsburg, PA | $298.20 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $13.3M
- Total Doctors 5
- Transactions 1,857
About SB623
SB623 is a drug associated with $13.3M in payments to 5 healthcare providers, recorded across 1,857 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2017 to 2019. In 2019, $2.3M was paid across 366 transactions to 1 doctors.
The most common payment nature for SB623 is "Unspecified" ($13.3M, 100.0% of total).
SB623 is associated with 2 research studies, including "Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke (ACTIsSIMA)" ($9.2M).